Mr. Makov is the former President & CEO of Teva Pharmaceutical Industries Ltd (2002-2007). He is among Israel’s most respected corporate leaders and is widely credited with making Teva the world’s leader of generic pharmaceuticals. Mr. Makov led Teva through an aggressive M&A strategy, leading record breaking acquisitions of: Biogal (1995), Novopharm (1999), Sicor (2004) and IVAX (2006). During Makov’s tenure as CEO, the company’s sales increased over four-fold, to approximately $8.5 billion, and its adjusted net income increased approximately six-fold, to over $1.8 billion.
Prior to joining Teva, Mr. Makov led a number of companies in various industries, and founded Israel’s first biotech company, Interpharm, which later went public in the US. Mr. Makov is a member of the Board of Directors of the Israel National Nanotechnology Initiative, an initiative he also helped establish. He is a member of the Executive Board & Management Committee of the Weizmann Institute of Science and the Chairman of the Board of the Institute for Policy and Strategy at the Interdisciplinary Center of Herzliya. Israel Makov holds a B.Sc. in Agriculture and M. Sc in Economics from the Hebrew University in Jerusalem.
